A water soluble biocompatible adhesive is provided comprising one or more compounds of structure 1 wherein B is an oligomer derived from a polyether or polyalkylene glycol, with a MW<5,000 g/mol, Linker L is a urethane, urea bond, or amide bond; Linker L′ is a urethane or urea bond, A is a chain extender of Mw≤3000 g/mol comprising substituted or unsubstituted alkyl, cycloalkyl and/or aromatic groups, W is a terminal adhesive benzene-1,2-diol derivative or a terminal adhesive benzene-1,2,3-diol derivative, m is 0 or 1; and n is 0, 1, 2, 3 or 4. The compound(s) have a Tg lower than 25° C. The biocompatible adhesive is suitable for use without solvent.

A water soluble biocompatible adhesive is provided comprising one or more compounds of structure 1 wherein B is an oligomer derived from a polyether or polyalkylene glycol, with a MW<5,000 g/mol, Linker L is a urethane, urea bond, or amide bond; Linker L′ is a urethane or urea bond, A is a chain extender of Mw≤3000 g/mol comprising substituted or unsubstituted alkyl, cycloalkyl and/or aromatic groups, W is a terminal adhesive benzene-1,2-diol derivative or a terminal adhesive benzene-1,2,3-diol derivative, m is 0 or 1; and n is 0, 1, 2, 3 or 4. The compound(s) have a Tg lower than 25° C. The biocompatible adhesive is suitable for use without solvent.

Compositions and methods are directed to engineered extracellular matrix protein—mussel foot protein fusions for use as a bioadhesive for repairing tissues. The compositions have one or more of: (i) at least one hydrophobic region; (ii) at least one crosslinking region; (iii) at least one tyrosine residue accessible to be enzymatically modified to a DOPA or TOPA side chain; (iv) at least one mussel foot protein; (v) at least one mussel foot protein loop; (vi) at least one human extracellular protein loop; or (vii) at least one of the following sequences: SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, or SEQ ID NO: 6. The elastin-like polypeptide includes at least one non-naturally occurring amino acid or sequence alteration.

The invention provides injectable, tough hydrogels that can be crosslinked in situ on demand using minimally-invasive methods, such as visible light exposure is an unmet medical challenge. Among the emerging biopolymers for tissue sealing, gelatin methacryloyl (GelMA), a naturally-derived biopolymer obtained from denatured collagen, has secured a promising role as a result of its excellent bioadhesion, biodegradation, and biocompatibility. To overcome one of the main shortcomings of GelMA, i.e., brittleness, we hybridized it using methacrylate-modified alginate (AlgMA) to impart ion-induced reversible crosslinking that can dissipate energy under strain. The hybrid GelMA-AlgMA hydrogels provide a photocrosslinkable, injectable, and adhesive platform with an excellent toughness that can be engineered using divalent cations, such as calcium. This class of novel hybrid biopolymers with more than 600% improved toughness may set the stage for durable, mechanically-resilient, and cost-effective tissue sealants in minimally invasive procedure, especially for stretchable tissues.

The present disclosure provides a biocompatible polymer, and the polymer includes the embolic microbead including an iron adsorption block capable of adsorbing an iron component. The embolic microbead according to the an exemplary embodiment of the present disclosure adsorbs iron and thus effectively blocks an iron component delivered to cancer cells, and when used in embolization, it has an improved effect in treating cancers, such as liver cancer.

The present disclosure provides a biocompatible polymer, and the polymer includes the embolic microbead including an iron adsorption block capable of adsorbing an iron component. The embolic microbead according to the an exemplary embodiment of the present disclosure adsorbs iron and thus effectively blocks an iron component delivered to cancer cells, and when used in embolization, it has an improved effect in treating cancers, such as liver cancer.

Adhesives comprising rubber, tackifier, oil, and optionally absorbent and active ingredient are described. The adhesives are suitable for medical applications as they are repositionable on skin. Also described are medical articles using the adhesives.

Adhesives comprising rubber, tackifier, oil, and optionally absorbent and active ingredient are described. The adhesives are suitable for medical applications as they are repositionable on skin. Also described are medical articles using the adhesives.

The subject matter of the invention is an autopolymerisable 2-component prosthetic base material, a kit containing the material as well as a method for its production comprising at least one liquid monomer component (A), and at least one powdered component (B), wherein the prosthetic material in component (A) besides methylmethacrylate contains at least one N-alkyl-substituted acryloyloxy carbamate having a molecular mass of less than or equal to 250 g/mol, optionally at least one at least di-functional urethane (meth)acrylate, a di-, tri-, tetra- or multi-functional monomer not being urethane (meth)acrylate, and optionally polymeric particles having a primary particle size of less than 800 nm, and the powdered component (B) comprises polymeric particles having at least three different particle size fractions, and both (A) and (B) contains at least one initiator or at least one component of an initiator system for autopolymerisation.

The subject matter of the invention is an autopolymerisable 2-component prosthetic base material, a kit containing the material as well as a method for its production comprising at least one liquid monomer component (A), and at least one powdered component (B), wherein the prosthetic material in component (A) besides methylmethacrylate contains at least one N-alkyl-substituted acryloyloxy carbamate having a molecular mass of less than or equal to 250 g/mol, optionally at least one at least di-functional urethane (meth)acrylate, a di-, tri-, tetra- or multi-functional monomer not being urethane (meth)acrylate, and optionally polymeric particles having a primary particle size of less than 800 nm, and the powdered component (B) comprises polymeric particles having at least three different particle size fractions, and both (A) and (B) contains at least one initiator or at least one component of an initiator system for autopolymerisation.